199 related articles for article (PubMed ID: 28864618)
1. Theranostics Using Antibodies and Antibody-Related Therapeutics.
Moek KL; Giesen D; Kok IC; de Groot DJA; Jalving M; Fehrmann RSN; Lub-de Hooge MN; Brouwers AH; de Vries EGE
J Nucl Med; 2017 Sep; 58(Suppl 2):83S-90S. PubMed ID: 28864618
[TBL] [Abstract][Full Text] [Related]
2. PET radiometals for antibody labeling.
Aluicio-Sarduy E; Ellison PA; Barnhart TE; Cai W; Nickles RJ; Engle JW
J Labelled Comp Radiopharm; 2018 Jul; 61(9):636-651. PubMed ID: 29341227
[TBL] [Abstract][Full Text] [Related]
3. Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET.
Verel I; Visser GW; Boerman OC; van Eerd JE; Finn R; Boellaard R; Vosjan MJ; Stigter-van Walsum M; Snow GB; van Dongen GA
Cancer Biother Radiopharm; 2003 Aug; 18(4):655-61. PubMed ID: 14503961
[TBL] [Abstract][Full Text] [Related]
4. Using antibodies to target cancer therapeutics.
Goldenberg DM; Sharkey RM
Expert Opin Biol Ther; 2012 Sep; 12(9):1173-90. PubMed ID: 22650606
[TBL] [Abstract][Full Text] [Related]
5. Biodistribution of (125)I-labeled anti-endoglin antibody using SPECT/CT imaging: Impact of in vivo deiodination on tumor accumulation in mice.
Karmani L; Levêque P; Bouzin C; Bol A; Dieu M; Walrand S; Vander Borght T; Feron O; Grégoire V; Bonifazi D; Michiels C; Lucas S; Gallez B
Nucl Med Biol; 2016 Jul; 43(7):415-23. PubMed ID: 27179250
[TBL] [Abstract][Full Text] [Related]
6. Theranostic applications of antibodies in oncology.
Fleuren ED; Versleijen-Jonkers YM; Heskamp S; van Herpen CM; Oyen WJ; van der Graaf WT; Boerman OC
Mol Oncol; 2014 Jun; 8(4):799-812. PubMed ID: 24725480
[TBL] [Abstract][Full Text] [Related]
7. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor.
Smith-Jones PM; Vallabhajosula S; Navarro V; Bastidas D; Goldsmith SJ; Bander NH
J Nucl Med; 2003 Apr; 44(4):610-7. PubMed ID: 12679407
[TBL] [Abstract][Full Text] [Related]
8. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies.
Verel I; Visser GW; Boellaard R; Stigter-van Walsum M; Snow GB; van Dongen GA
J Nucl Med; 2003 Aug; 44(8):1271-81. PubMed ID: 12902418
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibody-based molecular imaging strategies and theranostic opportunities.
Dammes N; Peer D
Theranostics; 2020; 10(2):938-955. PubMed ID: 31903161
[TBL] [Abstract][Full Text] [Related]
10. Theranostics in immuno-oncology using nanobody derivatives.
Lecocq Q; De Vlaeminck Y; Hanssens H; D'Huyvetter M; Raes G; Goyvaerts C; Keyaerts M; Devoogdt N; Breckpot K
Theranostics; 2019; 9(25):7772-7791. PubMed ID: 31695800
[TBL] [Abstract][Full Text] [Related]
11. ⁸⁹Zr-Labeled Versus ¹²⁴I-Labeled αHER2 Fab with Optimized Plasma Half-Life for High-Contrast Tumor Imaging In Vivo.
Mendler CT; Gehring T; Wester HJ; Schwaiger M; Skerra A
J Nucl Med; 2015 Jul; 56(7):1112-8. PubMed ID: 25999431
[TBL] [Abstract][Full Text] [Related]
12. The Current Status and Future Potential of Theranostics to Diagnose and Treat Childhood Cancer.
Poot AJ; Lam MGEH; van Noesel MM
Front Oncol; 2020; 10():578286. PubMed ID: 33330054
[TBL] [Abstract][Full Text] [Related]
13. [An overview of antibody-based cancer therapy].
Miao QF; Shao RG; Zhen YS
Yao Xue Xue Bao; 2012 Oct; 47(10):1261-8. PubMed ID: 23289136
[TBL] [Abstract][Full Text] [Related]
14. ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment.
Lamberts LE; Menke-van der Houven van Oordt CW; ter Weele EJ; Bensch F; Smeenk MM; Voortman J; Hoekstra OS; Williams SP; Fine BM; Maslyar D; de Jong JR; Gietema JA; Schröder CP; Bongaerts AH; Lub-de Hooge MN; Verheul HM; Sanabria Bohorquez SM; Glaudemans AW; de Vries EG
Clin Cancer Res; 2016 Apr; 22(7):1642-52. PubMed ID: 26589435
[TBL] [Abstract][Full Text] [Related]
15. Tumor immunotargeting using innovative radionuclides.
Kraeber-Bodéré F; Rousseau C; Bodet-Milin C; Mathieu C; Guérard F; Frampas E; Carlier T; Chouin N; Haddad F; Chatal JF; Faivre-Chauvet A; Chérel M; Barbet J
Int J Mol Sci; 2015 Feb; 16(2):3932-54. PubMed ID: 25679452
[TBL] [Abstract][Full Text] [Related]
16. Molecular imaging in drug development: Update and challenges for radiolabeled antibodies and nanotechnology.
Colombo I; Overchuk M; Chen J; Reilly RM; Zheng G; Lheureux S
Methods; 2017 Nov; 130():23-35. PubMed ID: 28743635
[TBL] [Abstract][Full Text] [Related]
17. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen.
Smith-Jones PM; Vallabahajosula S; Goldsmith SJ; Navarro V; Hunter CJ; Bastidas D; Bander NH
Cancer Res; 2000 Sep; 60(18):5237-43. PubMed ID: 11016653
[TBL] [Abstract][Full Text] [Related]
18. Antibodies and associates: Partners in targeted drug delivery.
Kennedy PJ; Oliveira C; Granja PL; Sarmento B
Pharmacol Ther; 2017 Sep; 177():129-145. PubMed ID: 28315359
[TBL] [Abstract][Full Text] [Related]
19. Nuclear imaging in cancer theranostics.
Del Vecchio S; Zannetti A; Fonti R; Pace L; Salvatore M
Q J Nucl Med Mol Imaging; 2007 Jun; 51(2):152-63. PubMed ID: 17420716
[TBL] [Abstract][Full Text] [Related]
20. Immuno-PET: a navigator in monoclonal antibody development and applications.
van Dongen GA; Visser GW; Lub-de Hooge MN; de Vries EG; Perk LR
Oncologist; 2007 Dec; 12(12):1379-89. PubMed ID: 18165614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
